Table of Contents Author Guidelines Submit a Manuscript
Canadian Journal of Infectious Diseases and Medical Microbiology
Volume 19, Issue 3, Pages 219-226
http://dx.doi.org/10.1155/2008/161835
Original Article

Economic Evaluation of Voriconazole for the Treatment of Candidemia in Canadian Adults

Coleman Rotstein,1 Lael Cragin,2 Michel Laverdière,3 Gary Garber,4 Eric J Bow,5,6 Alissa Scalera,7 Craig Roberts,8 Sonja V Sorenson,9 and the Canadian Expert Panel

1Division of Infectious Diseases, Department of Medicine, McMaster University, Hamilton, Ontario, Canada
2Center for Health Economics, Epidemiology and Science Policy, United BioSource Corporation, Maryland, USA
3Department of Microbiology-Infectious Diseases, Hospital Maisonneauve-Rosemont, University of Montreal, Montreal, Quebec, Canada
4Division of Infectious Diseases, University of Ottawa, Ottawa, Ontario, Canada
5Department of Internal Medicine and Medical Microbiology, University of Manitoba, Canada
6Department of Medical Oncology and Haematology, CancerCare, Winnipeg, Manitoba, Canada
7Pfizer Canada Inc, Montreal, Quebec, Canada
8Pfizer Inc, Canada
9Center for Health Economics, Epidemiology and Science Policy, United BioSource Corporation, Maryland, USA

Received 27 February 2008; Accepted 27 February 2008

Copyright © 2008 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to Cite this Article

Coleman Rotstein, Lael Cragin, Michel Laverdière, et al., “Economic Evaluation of Voriconazole for the Treatment of Candidemia in Canadian Adults,” Canadian Journal of Infectious Diseases and Medical Microbiology, vol. 19, no. 3, pp. 219-226, 2008. https://doi.org/10.1155/2008/161835.